市場調査レポート
商品コード
1310551

遺伝子編集の世界市場:製品・サービス別、技術別、用途、エンドユーザー別 - 予測(~2028年)

Gene Editing Market by Product & Service, Technology, Application, End User - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 209 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
遺伝子編集の世界市場:製品・サービス別、技術別、用途、エンドユーザー別 - 予測(~2028年)
出版日: 2023年07月14日
発行: MarketsandMarkets
ページ情報: 英文 209 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の遺伝子編集の市場規模は、2023年の53億米ドルから2028年までに106億米ドルに達し、CAGRで15.0%の成長が予測されています。

政府資金の増加と、ゲノミクスプロジェクト数の増加が、市場にとって影響の大きい促進要因として浮上しています。2022年3月、米国国立衛生研究所(NIH)は遺伝子編集研究への資金提供を拡大し、追加プロジェクトに8,900万米ドルを割り当てた。同様に、欧州連合(EU)はHorizon 2020プログラムを立ち上げ、ゲノミクス研究と遺伝子編集プロジェクトを促進するために多額の財源を提供しています。さらに、中国、日本、韓国を含むいくつかの国は、遺伝子編集技術の進歩を促進するために、国営のゲノムプログラムを設立し、専用の資金を提供しています。

"予測期間中、遺伝子編集サービスがもっとも高い成長を示す見込み"

製品・サービスに基づいて、遺伝子編集市場は試薬・消耗品、ソフトウェア・システム、サービスに区分されます。遺伝子編集サービス市場には、シーケンシングサービス、データ解析、バイオインフォマティクスサービス、インフォマティクス、クリーンアップ、遺伝子発現、DNA合成サービスなどのその他のサービスが含まれます。さらに、サービスプロバイダーはカスタマイズされたシーケンシングサービスも提供しています。バイオメディカル用途におけるシーケンシングサービスの導入は、ゲノムシーケンシングの需要を高め、市場を後押しすると予想されます。

"製薬企業・バイオテクノロジー企業が2022年の市場で最大シェアを占める見込み"

エンドユーザーに基づいて、市場は製薬企業・バイオテクノロジー企業、学術・研究機関、その他のエンドユーザーに区分されます。その他のエンドユーザーには、診断企業、CRO, CDMOが含まれます。ファーマコゲノミクスなどの製薬用途における遺伝子編集の高い需要が、予測期間を通じてこのセグメントの優位性に寄与しています。医薬品開発におけるバイオマーカーのさまざまな用途により、バイオマーカーの重要性の高まりが、このセグメントにおけるゲノムのシステムとサービスの利用を促進すると予想されます。これに伴い、バイオテクノロジー企業も新しい治療薬を発見・開発するためにゲノムデータベースを構築しています。

"アジア太平洋は、予測期間中にもっとも高いCAGRを記録すると予測されています。"

市場は北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに区分されます。アジア太平洋は、研究への投資の増加や、生物の細胞や組織の遺伝子工学に向けた遺伝子合成の応用の増加により、市場の急成長が見込まれています。がんは日本における主な死因の1つとなっており、政府はその有病率と死亡率を減少させるためにさまざまな取り組みを行っています。例えば、医療研究開発機構は、日本再生医療プロジェクト、日本ゲノム医療プロジェクト、日本がん研究プロジェクトなど、多くの研究プロジェクトを行っています。日本市場では、先進技術を利用した製品やサービスを日本に導入し提供しようとする国内の組織と世界の主要企業とのさまざまな提携やパートナーシップも見られます。

当レポートでは、世界の遺伝子編集市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主要考察

  • 遺伝子編集市場の概要
  • 北米:遺伝子編集市場:製品・サービス別、国別(2022年)
  • 北米の遺伝子編集市場:用途別(2023年・2028年)

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 技術分析
  • サプライチェーンとバリューチェーンの分析
    • 遺伝子編集市場:サプライチェーン分析
    • バリューチェーン分析
  • 顧客のビジネスに影響を与える動向/混乱
  • 価格分析
  • 規制分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • 主な会議とイベント(2023年)
  • 主なステークホルダーと購入基準
    • 購入プロセスにおける主なステークホルダー
    • 遺伝子編集市場:購入基準
  • 特許分析

第6章 遺伝子編集市場:製品・サービス別

  • イントロダクション
  • 試薬・消耗品
  • ソフトウェア・システム
  • サービス

第7章 遺伝子編集市場:技術別

  • イントロダクション
  • CRISPR
  • TALEN
  • ZFN
  • アンチセンス
  • その他の技術

第8章 遺伝子編集市場:用途別

  • イントロダクション
  • 細胞株工学
  • 遺伝子工学
  • 創薬・開発
  • その他の用途

第9章 遺伝子編集市場:エンドユーザー別

  • イントロダクション
  • 製薬企業・バイオテクノロジー企業
  • 学術・研究機関
  • その他のエンドユーザー

第10章 遺伝子編集市場:地域別

  • イントロダクション
  • 北米
    • 北米:不況の影響
    • 米国
    • カナダ
  • 欧州
    • 欧州:不況の影響
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • アジア太平洋:不況の影響
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • ラテンアメリカ
    • ラテンアメリカ:不況の影響
    • ブラジル
    • その他のラテンアメリカ
    • 中東・アフリカ
    • 中東・アフリカ:不況の影響

第11章 競合情勢

  • 概要
  • 主な企業の戦略/有力企業
  • 市場シェア分析
  • 市場の主要企業の収益シェア分析
  • 企業の評価クアドラント(2022年)
  • 新興企業/中小企業の評価クアドラント(2022年)
  • 企業フットプリント分析
    • 製品/サービスのフットプリント分析
    • 地理的フットプリント分析
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • THERMO FISHER SCIENTIFIC
    • MERCK KGAA
    • GENSCRIPT
    • AGILENT TECHNOLOGIES
    • PERKINELMER
    • LONZA
    • TECAN LIFE SCIENCES
    • SANGAMO THERAPEUTICS
    • EDITAS MEDICINE
    • CRISPR THERAPEUTICS AG
    • PRECISION BIOSCIENCES
    • CELLECTIS S.A.
    • INTELLIA THERAPEUTICS
    • BLUEBIRD BIO INC.
    • REGENERON PHARMACEUTICALS INC.
    • AMSBIO
    • CREATIVE BIOGENE
    • SYNTHEGO CORPORATION
    • BEAM THERAPEUTICS
  • その他の企業
    • CARIBOU BIOSCIENCES
    • ORIGENE TECHNOLOGIES
    • NEW ENGLAND BIOLABS
    • INSCRIPTA
    • MAMMOTH BIOSCIENCES

第13章 付録

目次
Product Code: BT 3380

The gene editing market is projected to grow from USD 5.3 billion in 2023 to USD 10.6 billion by 2028 at a CAGR of 15.0%. Rising government funding and number of genomics projects has emerged as a high impact driver for the market. In March 2022, the US National Institutes of Health (NIH) expanded its funding for gene editing research, allocating USD 89 million for additional projects. Similarly, the European Union launched the Horizon 2020 program, providing substantial financial resources to promote genomics research and gene editing projects. Moreover, several countries, including China, Japan, and South Korea, have established national genomics programs and dedicated funding to drive advancements in gene editing technologies.

"Gene editing services to witness the highest growth during the forecast period."

Based on product & service, the gene editing market is segmented into reagents & consumables, software & systems, and services. The gene editing services market includes sequencing services; data analysis; bioinformatics services; and other services, such as informatics, cleanup, gene expression, and DNA synthesis services. Additionally, service providers also offer customized sequencing services. The introduction of sequencing services in biomedical applications is expected to boost the demand for genomic sequencing, subsequently boosting the gene editing market.

"Pharmaceutical & biotechnology companies accounted for the largest share of the global gene editing market in 2022."

Based on end users, the gene editing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Other end users include diagnostic companies, CROs, and CDMOs. High demand for gene editing in pharma applications such as pharmacogenomics has contributed to the dominance of this segment throughout the forecast period. The growing importance of biomarkers is expected to drive the use of genomic systems and services in this segment, owing to the various applications of biomarkers in drug development. With this, biotechnology companies are also building genomic databases to discover and develop new therapeutics.

"Asia Pacific is estimated to register the highest CAGR during the forecast period."

The gene editing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa (MEA). The Asia Pacific region is expected to be the fastest-growing market for gene editing due to the increasing investments in research and the rising applications of gene synthesis for the genetic engineering of cells and tissues of organisms. Cancer has become one of the leading causes of death in Japan, prompting the government to undertake various initiatives to reduce its prevalence and mortality. For example, the Agency for Medical Research and Development has undertaken many research projects, including the Japan Regenerative Medicine Project, Japan Genomic Medicine Project, and Japan Cancer Research Project. The market in Japan has also witnessed various collaborations and partnerships between local organizations and leading global players seeking to introduce and offer technologically advanced products and services in the country.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Respondent: Supply Side (70%) , Demand side (30%)
  • By Designation: C-level (55%), Director-level (20%), and Others (25%)
  • By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report

  • Merck KGaA (Germany)
  • Thermo Fisher Scientific, Inc. (US)
  • GenScript (China)
  • Agilent Technologies (US)
  • PerkinElmer (US)
  • Lonza (Switzerland)
  • Tecan Life Sciences (Switzerland)
  • Sangamo Therapeutics (US)
  • Editas Medicine (US)
  • CRISPR Therapeutics AG (Switzerland)
  • Precision Biosciences (US)
  • Cellectis S.A. (France)
  • Intellia Therapeutics (US)
  • Bluebird Bio, Inc. (US)
  • Regeneron Pharmaceuticals (US)
  • AMSBIO (England)
  • Creative Biogene (US)
  • Synthego Corporation (US)
  • Beam Therapeutics Inc. (US)
  • Caribou Biosciences, Inc. (US)
  • OriGene Technologies (US)
  • New England Biolabs (US)
  • Inscripta (US)
  • Mammoth Biosciences (US).

Research Coverage

This report studies the gene editing market based on product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total gene editing market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on gene editing offered by the top 25 players in the market. The report analyzes the gene editing market by product & service, technology, application, end user, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/services/technologies across key geographic regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the gene editing market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the gene editing market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: GENE EDITING MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 GENE EDITING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • 2.3 MARKET GROWTH RATE PROJECTIONS
    • FIGURE 6 GENE EDITING MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
    • FIGURE 7 GENE EDITING MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
  • 2.4 DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 9 GENE EDITING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 GENE EDITING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 GENE EDITING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 GENE EDITING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT: GENE EDITING MARKET, 2022

4 PREMIUM INSIGHTS

  • 4.1 GENE EDITING MARKET OVERVIEW
    • FIGURE 14 GROWING INVESTMENTS IN GENOMICS RESEARCH TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022)
    • FIGURE 15 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 NORTH AMERICA GENE EDITING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 CELL LINE ENGINEERING TO DOMINATE NORTH AMERICAN MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 GENOME EDITING MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising government funding and number of genomics projects
      • 5.2.1.2 Growing applications of genomics
      • 5.2.1.3 Introduction of CRISPR-Cas9
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Off-target effects of CRISPR technology
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Extensive use of genome editing in personalized medicine
      • 5.2.3.2 Expanding pipeline for gene therapy
    • 5.2.4 CHALLENGES
      • 5.2.4.1 High equipment costs
  • 5.3 TECHNOLOGY ANALYSIS
  • 5.4 SUPPLY AND VALUE CHAIN ANALYSIS
    • 5.4.1 GENE EDITING MARKET: SUPPLY CHAIN ANALYSIS
    • FIGURE 18 GENE EDITING MARKET: SUPPLY CHAIN ANALYSIS
    • 5.4.2 VALUE CHAIN ANALYSIS
    • FIGURE 19 GENE EDITING MARKET: VALUE CHAIN ANALYSIS
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.6 PRICING ANALYSIS
    • TABLE 5 AVERAGE SELLING PRICES, BY PRODUCT (KEY PLAYER OFFERINGS)
  • 5.7 REGULATORY ANALYSIS
    • 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 21 GENE EDITING MARKET: ECOSYSTEM ANALYSIS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 11 GENE EDITING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY CONFERENCES AND EVENTS IN 2023
    • TABLE 12 GENE EDITING MARKET: CONFERENCES AND EVENTS (2023)
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 22 GENE EDITING MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
    • 5.11.2 GENE EDITING MARKET: BUYING CRITERIA
    • FIGURE 23 KEY BUYING CRITERIA FOR GENE EDITING
  • 5.12 PATENT ANALYSIS
    • FIGURE 24 PATENTS GRANTED, JANUARY 2011-JUNE 2023
    • FIGURE 25 TOP PATENT APPLICANTS, JANUARY 2011-JUNE 2023

6 GENE EDITING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 13 GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 REAGENTS & CONSUMABLES
    • 6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE
    • TABLE 14 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 15 NORTH AMERICA: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 16 EUROPE: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 LATIN AMERICA: GENE EDITING REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 SOFTWARE & SYSTEMS
    • 6.3.1 INCREASING APPLICATIONS OF GENOME EDITING/SEQUENCING TO BOOST DEMAND FOR SYSTEMS AND SOFTWARE
    • TABLE 19 GENE EDITING SOFTWARE & SYSTEMS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 LATIN AMERICA: GENE EDITING SOFTWARE & SYSTEMS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 SERVICES
    • 6.4.1 RISING DEMAND FOR SERVICES TO SUPPORT GROWTH
    • TABLE 24 GENE EDITING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 LATIN AMERICA: GENE EDITING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 GENE EDITING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 29 GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 CRISPR
    • 7.2.1 EASE OF USE TO BOOST DEMAND OVER OTHER TECHNOLOGIES
    • TABLE 30 GENE EDITING MARKET FOR CRISPR, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 31 NORTH AMERICA: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 EUROPE: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 LATIN AMERICA: GENE EDITING MARKET FOR CRISPR, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 TALEN
    • 7.3.1 ABILITY TO MAKE QUICK MODIFICATIONS TO DRIVE USAGE
    • TABLE 35 GENE EDITING MARKET FOR TALEN, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 EUROPE: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 LATIN AMERICA: GENE EDITING MARKET FOR TALEN, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 ZFN
    • 7.4.1 UTILITY IN EUKARYOTE CELL STUDIES TO DRIVE MARKET GROWTH
    • TABLE 40 GENE EDITING MARKET FOR ZFN, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 LATIN AMERICA: GENE EDITING MARKET FOR ZFN, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 ANTISENSE
    • 7.5.1 INCREASED APPLICATION IN ENGINEERING HUMAN CELLS FOR DISEASE STUDY TO DRIVE MARKET GROWTH
    • TABLE 45 GENE EDITING MARKET FOR ANTISENSE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 LATIN AMERICA: GENE EDITING MARKET FOR ANTISENSE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.6 OTHER TECHNOLOGIES
    • TABLE 50 GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 LATIN AMERICA: GENE EDITING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)

8 GENE EDITING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 55 GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 8.2 CELL LINE ENGINEERING
    • 8.2.1 INCREASING RESEARCH APPLICATIONS TO PROMOTE MARKET GROWTH
    • TABLE 56 GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 LATIN AMERICA: GENE EDITING MARKET FOR CELL LINE ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 GENETIC ENGINEERING
    • 8.3.1 GROWING USE OF ANIMAL SIMULATION MODELS IN RESEARCH AND INCREASING INTEREST IN GM CROPS TO DRIVE MARKET
    • TABLE 61 GENE EDITING MARKET FOR GENETIC ENGINEERING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 LATIN AMERICA: GENE EDITING MARKET FOR GENETIC ENGINEERING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 DRUG DISCOVERY & DEVELOPMENT
    • 8.4.1 GROWING RESEARCH AND APPLICATIONS IN DRUG DISCOVERY & DEVELOPMENT TO BOOST GROWTH
    • TABLE 66 GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 LATIN AMERICA: GENE EDITING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER APPLICATIONS
    • TABLE 71 GENE EDITING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 LATIN AMERICA: GENE EDITING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

9 GENE EDITING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 76 GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 PHARMA & BIOTECH COMPANIES TO HOLD LARGEST MARKET SHARE
    • TABLE 77 GENE EDITING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 78 NORTH AMERICA: GENE EDITING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 EUROPE: GENE EDITING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: GENE EDITING MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 LATIN AMERICA: GENE EDITING MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 ACADEMIC & RESEARCH INSTITUTES
    • 9.3.1 TREND OF COLLABORATIVE RESEARCH TO SUPPORT MARKET GROWTH
    • TABLE 82 GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 LATIN AMERICA: GENE EDITING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 OTHER END USERS
    • TABLE 87 GENE EDITING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 LATIN AMERICA: GENE EDITING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

10 GENE EDITING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 92 GENE EDITING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 26 NORTH AMERICA: GENE EDITING MARKET SNAPSHOT
    • TABLE 93 NORTH AMERICA: GENE EDITING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 NORTH AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 95 NORTH AMERICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 96 NORTH AMERICA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 97 NORTH AMERICA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Robust investment to drive market growth
    • TABLE 98 US: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 99 US: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 100 US: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 101 US: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Availability of research funding to support growth
    • TABLE 102 CANADA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 103 CANADA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 104 CANADA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 105 CANADA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 106 EUROPE: GENE EDITING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 EUROPE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 108 EUROPE: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 109 EUROPE: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 110 EUROPE: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Strong academic base and rising awareness to boost market
    • TABLE 111 GERMANY: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 112 GERMANY: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 113 GERMANY: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 114 GERMANY: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Government support to boost market growth
    • TABLE 115 UK: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 116 UK: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 117 UK: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 118 UK: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Government funding for genomics and rising research investments to propel market
    • TABLE 119 FRANCE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 120 FRANCE: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 121 FRANCE: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 122 FRANCE: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing collaborations to drive genomic medicine research and favor market
    • TABLE 123 ITALY: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 124 ITALY: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 125 ITALY: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 126 ITALY: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Proactive research funding to boost market
    • TABLE 127 SPAIN: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 128 SPAIN: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 129 SPAIN: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 130 SPAIN: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 131 REST OF EUROPE: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 132 REST OF EUROPE: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 133 REST OF EUROPE: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 134 REST OF EUROPE: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 27 ASIA PACIFIC: GENE EDITING MARKET SNAPSHOT
    • TABLE 135 ASIA PACIFIC: GENE EDITING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 139 ASIA PACIFIC: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 China to hold largest share of APAC market
    • TABLE 140 CHINA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 141 CHINA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 142 CHINA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 143 CHINA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Focus on cancer research to showcase favorable scenarios for gene editing market
    • TABLE 144 JAPAN: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 145 JAPAN: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 146 JAPAN: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 147 JAPAN: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Growing startups and government support to boost growth potential
    • TABLE 148 INDIA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 149 INDIA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 150 INDIA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 151 INDIA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 152 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 153 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 154 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 155 REST OF ASIA PACIFIC: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 156 LATIN AMERICA: GENE EDITING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 157 LATIN AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 158 LATIN AMERICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 159 LATIN AMERICA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 160 LATIN AMERICA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.2 BRAZIL
      • 10.5.2.1 Brazil to dominate Latin American market
    • TABLE 161 BRAZIL: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 162 BRAZIL: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 163 BRAZIL: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 164 BRAZIL: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 165 REST OF LATIN AMERICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 166 REST OF LATIN AMERICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 167 REST OF LATIN AMERICA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 168 REST OF LATIN AMERICA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.4 MIDDLE EAST & AFRICA
      • 10.5.4.1 Increasing adoption of genetic testing to propel market
    • 10.5.5 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 169 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 170 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 171 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 172 MIDDLE EAST & AFRICA: GENE EDITING MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 28 KEY PLAYER STRATEGIES, 2020-2023
  • 11.3 MARKET SHARE ANALYSIS
    • TABLE 173 GENE EDITING MARKET: DEGREE OF COMPETITION
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 30 REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS (2020-2022)
  • 11.5 COMPANY EVALUATION QUADRANT, 2022
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 EMERGING COMPANIES
    • FIGURE 31 GENE EDITING MARKET: COMPANY EVALUATION QUADRANT, 2022
  • 11.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 32 GENE EDITING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
  • 11.7 COMPANY FOOTPRINT ANALYSIS
    • 11.7.1 PRODUCT/SERVICE FOOTPRINT ANALYSIS
    • TABLE 174 PRODUCT/SERVICE FOOTPRINT ANALYSIS: GENE EDITING MARKET (2022)
    • 11.7.2 GEOGRAPHIC FOOTPRINT ANALYSIS
    • TABLE 175 GEOGRAPHIC FOOTPRINT ANALYSIS: GENE EDITING MARKET (2022)
  • 11.8 COMPETITIVE SCENARIO

12 COMPANY PROFILES

  • 12.1 KEY COMPANIES
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 THERMO FISHER SCIENTIFIC
    • TABLE 176 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 12.1.2 MERCK KGAA
    • TABLE 177 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 12.1.3 GENSCRIPT
    • TABLE 178 GENSCRIPT: BUSINESS OVERVIEW
    • FIGURE 35 GENSCRIPT: COMPANY SNAPSHOT (2022)
    • 12.1.4 AGILENT TECHNOLOGIES
    • TABLE 179 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 36 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022)
    • 12.1.5 PERKINELMER
    • TABLE 180 PERKINELMER: BUSINESS OVERVIEW
    • FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2022)
    • 12.1.6 LONZA
    • TABLE 181 LONZA: BUSINESS OVERVIEW
    • FIGURE 38 LONZA: COMPANY SNAPSHOT (2022)
    • 12.1.7 TECAN LIFE SCIENCES
    • TABLE 182 TECAN LIFESCIENCES: BUSINESS OVERVIEW
    • FIGURE 39 TECAN LIFESCIENCES: COMPANY SNAPSHOT (2022)
    • 12.1.8 SANGAMO THERAPEUTICS
    • TABLE 183 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW
    • FIGURE 40 SANGAMO THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • 12.1.9 EDITAS MEDICINE
    • TABLE 184 EDITAS MEDICINE: BUSINESS OVERVIEW
    • FIGURE 41 EDITAS MEDICINE: COMPANY SNAPSHOT (2022)
    • 12.1.10 CRISPR THERAPEUTICS AG
    • TABLE 185 CRISPR THERAPEUTICS AG: BUSINESS OVERVIEW
    • FIGURE 42 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT (2022)
    • 12.1.11 PRECISION BIOSCIENCES
    • TABLE 186 PRECISION BIOSCIENCES: BUSINESS OVERVIEW
    • FIGURE 43 PRECISION BIOSCIENCES: COMPANY SNAPSHOT (2020)
    • 12.1.12 CELLECTIS S.A.
    • TABLE 187 CELLECTIS: BUSINESS OVERVIEW
    • FIGURE 44 CELLECTIS: COMPANY SNAPSHOT (2022)
    • 12.1.13 INTELLIA THERAPEUTICS
    • TABLE 188 INTELLIA THERAPEUTICS: BUSINESS OVERVIEW
    • FIGURE 45 INTELLIA THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • 12.1.14 BLUEBIRD BIO INC.
    • TABLE 189 BLUEBIRD BIO: BUSINESS OVERVIEW
    • FIGURE 46 BLUEBIRD BIO: COMPANY SNAPSHOT (2022)
    • 12.1.15 REGENERON PHARMACEUTICALS INC.
    • TABLE 190 REGENERON PHARMACEUTICALS: BUSINESS OVERVIEW
    • FIGURE 47 REGENERON PHARMACEUTICALS: COMPANY SNAPSHOT (2022)
    • 12.1.16 AMSBIO
    • TABLE 191 AMSBIO: BUSINESS OVERVIEW
    • 12.1.17 CREATIVE BIOGENE
    • TABLE 192 CREATIVE BIOGENE: BUSINESS OVERVIEW
    • 12.1.18 SYNTHEGO CORPORATION
    • TABLE 193 SYNTHEGO CORPORATION: BUSINESS OVERVIEW
    • 12.1.19 BEAM THERAPEUTICS
    • TABLE 194 BEAM THERAPEUTICS: BUSINESS OVERVIEW
    • FIGURE 48 BEAM THERAPEUTICS: COMPANY SNAPSHOT (2022)
  • 12.2 OTHER PLAYERS
    • 12.2.1 CARIBOU BIOSCIENCES
    • 12.2.2 ORIGENE TECHNOLOGIES
    • 12.2.3 NEW ENGLAND BIOLABS
    • 12.2.4 INSCRIPTA
    • 12.2.5 MAMMOTH BIOSCIENCES
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS